25 results
6-K
EX-10.4
MREO
Mereo Biopharma Group Plc
5 Jun 20
Mereo BioPharma Announces Completion of $70 Million Private Placement
12:00am
with the Black-Scholes Option Pricing formula set forth inAppendix (A) hereto, without regard to any limitations on exercise contained in such Warrants … is determined in accordance with the Black-Scholes Option Pricing formula set forthAppendix (B) hereto, without regard to any limitations on exercise
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
2 Nov 22
Current report (foreign)
4:17pm
.
The weighted average exercise price is $1.24 per ADS.
Options over ADSs issued during the six months ended June 30, 2022 were valued using the Black … )
Market price of ADS($)
Model used
Black-Scholes
Volatility was estimated by reference to the one year historical volatility of the historical share price
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
2 Nov 21
Current report (foreign)
4:16pm
is $2.81.
Options over ADSs issued during the six months ended June 30, 2021 were valued using the Black-Scholes model with the following weighted … -free interest rate (%)
Expected life of share options (years)
Market price of ADS($)
Model used
Black-Scholes
Volatility was estimated by reference
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
7 Sep 23
Current report (foreign)
7:37am
June 30, 2023, were valued using the Black-Scholes model with the following weighted average inputs: expected volatility of
98.06%; risk free … the six months ended June 30, 2023 were valued using the Black-Scholes model with the following inputs: expected volatility of
97.94%; risk free
6-K
EX-99.2
MREO
Mereo Biopharma Group Plc
29 Sep 20
Current report (foreign)
7:08am
a discounted cash flow model as well as Black Scholes model for the hybrid contract.
The following table lists the inputs into the model used to fair value … of resolutions passing (%)
Model used
Discounted Cash
flow/Black
Scholes model
Discounted Cash
flow/Black
Scholes model
Volatility was estimated
F-4
EX-99.1
2xikcev7e
25 Jan 19
Registration of securities (foreign)
12:00am
425
rqvuiq2jx
7 Jan 19
Business combination disclosure
11:50am
425
720lyn
11 Dec 18
Business combination disclosure
1:16pm
10-K
EX-19.1
mqie 39rr
27 Mar 24
Annual report
5:20pm
10-Q
99x5gi7 1p
15 May 24
Quarterly report
4:19pm
425
9xp0ejjlrj
12 Mar 19
Business combination disclosure
9:27am
6-K
EX-10.1
fdg8vueyq 9eb
5 Jun 20
Mereo BioPharma Announces Completion of $70 Million Private Placement
12:00am
6-K
x5abs3it7r
29 Apr 19
Current report (foreign)
12:09pm
6-K
1tr9y60yypr 9h
17 Sep 19
Current report (foreign)
8:06am
425
r5yffzfh5hgqq3k1 ts
15 Feb 19
Business combination disclosure
6:50am
425
zdxt cx5wm
12 Feb 19
Business combination disclosure
12:00am
6-K
bawmx8
16 Jun 20
Current report (foreign)
4:13pm
F-1/A
k81fow5
12 Mar 20
Registration statement (foreign) (amended)
5:15pm
F-1/A
48rlr
6 Mar 20
Registration statement (foreign) (amended)
5:32pm